BioQuiddity and Lee’s Pharmaceutical Enter Agreement
News Aug 28, 2015
BioQuiddity Incorporated and Lee’s Pharmaceutical (HK) Limited have announced the signing of a strategic license and supply agreement for the registration and commercialization of BioQuiddity’s ropivacaine and propofol infusion pharmaceutical products in the People’s Republic of China, Taiwan, Hong Kong, and Macau.
BioQuiddity’s unit-dose infusible pharmaceuticals are comprised of the pharmaceutical, delivery system and administration line in a self-contained, single use, ready-to-use presentation. The ropivacaine pharmaceutical is prefilled with 0.2% ropivacaine and is intended to provide a safer, more efficient continuous-infusion post-operative pain solution. BioQuiddity’s propofol infusion pharmaceutical features both programmable flow and bolus capabilities.
Josh Kriesel, President and CEO of BioQuiddity, stated, “We are excited to collaborate with Lee’s Pharm as we pursue our goal of setting a new standard of care in the presentation and administration of infusible pharmaceuticals throughout the world. Lee’s Pharm’s extensive infrastructure and proven marketing team will be the key in bringing BioQuiddity’s proprietary unit-dose, large volume infusion pharmaceuticals to the Asia Pacific region. We are extremely pleased to add another distinguished partner to our worldwide network.”
Dr. Li Xiaoyi, Executive Director and Chief Executive Officer of Lee’s Pharm, remarked, “We are honored to partner with BioQuiddity to bring the two unit-dose infusion pharmaceuticals to the Greater China market. BioQuiddity’s infusion pharmaceuticals offer a new and differentiated mode of bringing infusible pharmaceuticals to our customers and to patients.”
Concept Life Sciences appoints New Group Programme Manager and US Head of SalesNews
Key leadership appointments support integration of the Group and expansion in the US market.READ MORE
Alzheimer’s Drug Discovery Foundation Announces $1.8M in New FundingNews
The Alzheimer’s Drug Discovery Foundation (ADDF) announces nearly $1.8 million in new funding, which reflects a commitment to advancing drugs in or near human clinical trials. All five funded programs are potential treatments for Alzheimer’s disease and other forms of dementia.READ MORE